Diabetes, Vol 40, Issue 11 1488-1495, Copyright © 1991 by American Diabetes Association

ARTICLES

Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells

K Drejer, V Kruse, UD Larsen, P Hougaard, S Bjorn and S Gammeltoft
Novo Research Institute, Bagsvaerd, Denmark.

The insulin-receptor affinity of five human insulin analogues with one to four amino acid substitutions was measured with human hepatoma cells (HepG2). The binding affinities ranged from 0.05% for AspB25 insulin, 18% for AspB9, GluB27 insulin, 80% for AspB28 insulin, and 327% for AspB10 insulin to 687% for HisA8, HisB4, GluB10, HisB27 insulin relative to human insulin. Binding constants obtained by competition experiments at steady state with [125I]TyrA14-labeled insulin and unlabeled analogues and by kinetic studies with [125I]TyrA14-labeled analogues and insulin gave essentially the same values. The kinetic studies showed that differences in affinity between analogues were due to differences in both dissociation and association rate constants. The affinity for insulinlike growth factor I receptor was low, ranging from less than 0.005% for AspB25 insulin to 0.6% for HisA8, HisB4, GluB10, HisB27 insulin. The potencies of insulin analogues in activation of the tyrosine kinase of solubilized and partially purified insulin receptors from HepG2 cells, measured with the exogenous substrate poly(Glu80-Tyr20), ranked in the same order as the binding affinities, the actual values being somewhat elevated for the high-affinity analogues, however. We conclude that these human insulin analogues are active in insulin-receptor binding and tyrosine kinase stimulation but show wide variation in affinity.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				I. Rakatzi, S. Ramrath, D. Ledwig, O. Dransfeld, T. Bartels, G. Seipke, and J. Eckel A Novel Insulin Analog With Unique Properties: LysB3,GluB29 Insulin Induces Prominent Activation of Insulin Receptor Substrate 2, but Marginal Phosphorylation of Insulin Receptor Substrate 1 Diabetes, September 1, 2003; 52(9): 2227 - 2238. [Abstract] [Full Text] [PDF]

				A. Lindholm, L. B. Jensen, P. D. Home, P. Raskin, B. O. Boehm, and J. Rastam Immune Responses to Insulin Aspart and Biphasic Insulin Aspart in People With Type 1 and Type 2 Diabetes Diabetes Care, May 1, 2002; 25(5): 876 - 882. [Abstract] [Full Text] [PDF]

				Z. Vajo, J. Fawcett, and W. C. Duckworth Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs Endocr. Rev., October 1, 2001; 22(5): 706 - 717. [Abstract] [Full Text] [PDF]

				F. Authier, G. M. Danielsen, M. Kouach, G. Briand, and G. Chauvet Identification of Insulin Domains Important for Binding to and Degradation by Endosomal Acidic Insulinase Endocrinology, January 1, 2001; 142(1): 276 - 289. [Abstract] [Full Text] [PDF]

				Z. Vajo and W. C. Duckworth Genetically Engineered Insulin Analogs: Diabetes in the New Millenium Pharmacol. Rev., March 1, 2000; 52(1): 1 - 10. [Abstract] [Full Text] [PDF]

				D. C. Mynarcik, P. F. Williams, L. Schaffer, G. Q. Yu, and J. Whittaker Identification of Common Ligand Binding Determinants of the Insulin and Insulin-like Growth Factor 1 Receptors. INSIGHTS INTO MECHANISMS OF LIGAND BINDING J. Biol. Chem., July 25, 1997; 272(30): 18650 - 18655. [Abstract] [Full Text] [PDF]

				D. C. Mynarcik, P. F. Williams, L. Schaffer, G. Q. Yu, and J. Whittaker Analog Binding Properties of Insulin Receptor Mutants. IDENTIFICATION OF AMINO ACIDS INTERACTING WITH THE COOH TERMINUS OF THE B-CHAIN OF THE INSULIN MOLECULE J. Biol. Chem., January 24, 1997; 272(4): 2077 - 2081. [Abstract] [Full Text] [PDF]